Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione

Citation
Dw. Voehringer et Re. Meyn, Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione, DRUG RESIST, 1(6), 1998, pp. 345-351
Citations number
66
Categorie Soggetti
Pharmacology & Toxicology
Journal title
DRUG RESISTANCE UPDATES
ISSN journal
13687646 → ACNP
Volume
1
Issue
6
Year of publication
1998
Pages
345 - 351
Database
ISI
SICI code
1368-7646(1998)1:6<345:RDRIBT>2.0.ZU;2-2
Abstract
The immense research effort in cancer cell physiology has led to an appreci ation of the molecular and biochemical pathways that regulate cellular resp onses to endogenous and exogenous insults. Similarly, in tumor cells, there are multiple overlapping pathways that, once activated, impart resistance to therapeutic intervention. The multi drug resistance pathway is one such pathway. In this review, we will present current ideas concerning a mechani sm of tumor cell resistance that involves the inability to undergo apoptosi s. The bcl-2 family of proteins are known to regulate apoptosis in response to a wide variety of toxic agents. Additionally, recent evidence points to bcl-2 involvement in the regulation of antioxidant pathways mediated by gl utathione. This new information will be discussed in some detail and strate gies for overcoming these resistance mechanisms that may have clinical util ity will be presented.